188 related articles for article (PubMed ID: 12494247)
1. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
Welge JA; Keck PE
Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
[TBL] [Abstract][Full Text] [Related]
2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
3. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine in schizophrenia: onset of action within the first week of treatment.
Small JG; Kolar MC; Kellams JJ
Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
Kimko HC; Reele SS; Holford NH; Peck CC
Clin Pharmacol Ther; 2000 Nov; 68(5):568-77. PubMed ID: 11103759
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
9. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
Leucht S; Busch R; Hamann J; Kissling W; Kane JM
Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
[TBL] [Abstract][Full Text] [Related]
10. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis.
Paton C; Whittington C; Barnes TR
J Clin Psychopharmacol; 2007 Apr; 27(2):198-204. PubMed ID: 17414246
[TBL] [Abstract][Full Text] [Related]
11. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
12. Placebo or active control trials of antipsychotic drugs?
Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J
Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
14. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
17. Comparative remission rates of schizophrenic patients using various remission criteria.
Beitinger R; Lin J; Kissling W; Leucht S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
[TBL] [Abstract][Full Text] [Related]
18. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.
Loder E; Goldstein R; Biondi D
Cephalalgia; 2005 Feb; 25(2):124-31. PubMed ID: 15658949
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
Mishara AL; Goldberg TE
Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
[TBL] [Abstract][Full Text] [Related]
20. Placebo responses in randomized trials of antiepileptic drugs.
Guekht AB; Korczyn AD; Bondareva IB; Gusev EI
Epilepsy Behav; 2010 Jan; 17(1):64-9. PubMed ID: 19919904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
